CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman

Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience.

Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success in closing multi-billion-dollar total company and asset sales to S&P 500 companies.

OXNARD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of former CEO Rob Davidson to Chairman of the Board of Directors. In addition, the Company announced the appointment of Robert J. Costantino to its board of directors and he has also been appointed as the Chairman of CURE’s Audit Committee. These appointments bring decades of financial experience, as well as continuity that should enhance the company’s shareholder value initiatives and communications.

Rob Davidson was most recently CURE’s Chief Executive Officer from July 2011 to July 2022 and served as Chairman of our Board until January 2019. He continues with the company in the key roles of product development, creating new patents and on-going negotiations of non-dilutive deal transactions. Prior to his role at CURE Pharmaceutical, Robert Davidson served as Chief Executive Officer of InnoZen Inc., Gel Tech LLC, and Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Zicam, Chloraseptic, Suppress, as well as Pediastrip, a private label electrolyte oral thin film sold in major drug store chains.

“I am elated to be returning as CURE’s Chairman, while concurrently being committed to the development of new and innovative products and continuing to work on additional non-dilutive transactions and other initiatives to enhance shareholder value during this exciting transitional time. I would like our shareholders to take my accepting of the Chairman’s roll as a renewed commitment to the company and its investors and understand that everything we do going forward will have shareholder value as a primary focus. I will be supporting our new management and would like to commend Nancy Duitch and her team for what they have built during these difficult past couple of years, despite limited funding. We were always committed to getting The Sera Labs subsidiary the marketing funds it needed to achieve growth and now the team is poised for success. I am also excited to continue to work with Nancy as CEO to help the holding company add new brands, patents and products,” said Mr. Davidson, newly appointed Chairman of the Board of CURE.